NCT02341079

Brief Summary

The purpose of the study is to evaluate the efficacy of local infiltration of liposomal bupivacaine versus use of an indwelling femoral peripheral nerve block in controlling early postoperative pain in primary total knee arthroplasty. The investigators hope to demonstrate equivalency of treatment modalities to provide an alternative to the commonly used treatment of femoral nerve blockade.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

January 19, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

March 1, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2015

Completed
Last Updated

March 10, 2017

Status Verified

March 1, 2017

Enrollment Period

7 months

First QC Date

January 14, 2015

Last Update Submit

March 7, 2017

Conditions

Keywords

Total Knee ArthroplastyOsteoarthritisFemoral Nerve BlockadeLiposomal Bupivacaine

Outcome Measures

Primary Outcomes (3)

  • Visual Analog Pain Scale

    10cm VAS scale completed by the patient at set intervals postoperatively

    0-3 months

  • Oral and Intravenous Opioid Consumption

    Oral and intravenous opioid use calculated in terms of morphine equivalents

    0-5 days (during hospitalization)

  • Hospital for Special Surgery (HSS) Knee Scores

    Standardized functional clinical score for knee symptoms

    0-3 months

Secondary Outcomes (6)

  • Length of Hospital Stay

    0-5 days

  • Distance ambulated with physical therapy

    0-5 days (during hospitalization)

  • Time to straight leg raise with physical therapy

    0-5 days (during hospitalization)

  • Postoperative range of motion

    0-3 months

  • Postoperative complication rate

    0-3 months

  • +1 more secondary outcomes

Study Arms (2)

Femoral Nerve Blockade

ACTIVE COMPARATOR

Femoral nerve block delivered via indwelling femoral nerve catheter

Drug: Indwelling femoral nerve block

Bupivacaine Liposome Injection

EXPERIMENTAL

Intraoperative intracapsular injection of bupivacaine liposome

Drug: Bupivacaine Liposome Injection

Interventions

Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.

Also known as: EXPAREL
Bupivacaine Liposome Injection

Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.

Femoral Nerve Blockade

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age over 18 years old
  • Undergoing unilateral primary total knee arthroplasty

You may not qualify if:

  • Revision total knee arthroplasty
  • Bilateral total knee arthroplasty
  • Prior allergy or adverse reaction to local anesthetic
  • Hepatic dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Naval Medical Center San Diego

San Diego, California, 92134, United States

Location

MeSH Terms

Conditions

OsteoarthritisOsteoarthritis, Knee

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • Patrick B Morrissey, M.D.

    Naval Medical Center San Diego Department of Orthopadic Surgery

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 14, 2015

First Posted

January 19, 2015

Study Start

March 1, 2015

Primary Completion

October 1, 2015

Study Completion

October 1, 2015

Last Updated

March 10, 2017

Record last verified: 2017-03

Locations